Corona Remedies IPO Day 1 Highlights: Issue booked 62% on first day; GMP, review, other key details. Apply or not?

Corona Remedies IPO Day 1 Highlights: The Corona Remedies IPO was subscribed 62% as of the first day of public bidding on Monday, 8 December 2025. The issue received bids for 28,17,234 shares as against 45,71,882 shares on the offer.

The NSE data shows that the retail investor portion witnessed the most bookings with 87% subscription as the bidders opted for 19,67,756 shares out of the total 22,55,281 shares on offer for the segment.

The Non-Institutional Investors (NIIs) portion was booked 79%, as investors bid for 7,64,064 shares, compared to the 9,66,549 shares on offer. The Qualified Institutional Buyers (QIB) portion received flat booking as investors subscribed for 2,716 shares, compared to the 12,88,732 shares on offer.

Corona Remedies IPO Day 1 LIVE: As of Monday, 8 December 2025, the grey market premium of the Corona Remedies IPO stands at ₹290 per share. With the upper price band of the public issue at ₹1,062 apiece, the company's stocks are expected to be listed at ₹1,352 per share, marking a potential listing gain of 27%, according to IPO India data.

Grey market premium (GMP) in an indicator of investors' willingness to invest into a primary issue on the stock market.

Corona Remedies IPO Day 1 LIVE: The Corona Remedies IPO was subscribed 62% as of the first day of public bidding on Monday, 8 December 2025. The investors booked 28,17,234 shares out of the total 45,71,882 shares available for the investors.

The BSE data shows that so far, the retail investor portion witnessed the most bookings with 87% subscription as the bidders booked 19,67,756 shares out of the total 22,55,281 shares on offer for the segment.

The Non-Institutional Investors (NIIs) portion was booked 79%, as investors bid for 7,64,064 shares, compared to the 9,66,549 shares on offer. The Qualified Institutional Buyers (QIB) portion received flat booking as investors subscribed for 2,716 shares, compared to the 12,88,732 shares on offer.

Corona Remedies IPO Day 1 LIVE: The Corona Remedies IPO has been subscribed 61% so far as of the first day of public bidding on Monday, 8 December 2025, according to the BSE data.

Stock market investors booked 27,98,502 shares out of the total 45,71,882 shares available for the IPO round.

Corona Remedies IPO Day 1 LIVE: Corona Remedies’ revenue has grown at a CAGR of 16.3% during FY23-25.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO has been subscribed 42% so far, according to NSE data as of 2:00 PM on Monday, the first day of the bidding process. The public issue is booked 63% in the Retail Individual Investors category, and 46% in the Non-Institutional Investors (NII) segment. The Qualified Institutional Buyers (QIB) are yet to bid for the IPO so far.

Corona Remedies IPO Day 1 LIVE: Corona Remedies’ volume growth remains a key differentiator, with the company recording 5.70% growth versus IPM’s 2.15%, underscoring its ability to capture market share through effective execution. Strategic initiatives — including recent acquisitions, successful turnarounds, and investment in La Chandra (female hormone API manufacturing) — position the company for sustained expansion in high‑potential therapeutic categories.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO has been subscribed 38% so far, according to NSE data as of 1:20 PM on Monday, the first day of the bidding process. The public issue is booked 56% in the Retail Individual Investors category, and 41% in the Non-Institutional Investors (NII) segment. The Qualified Institutional Buyers (QIB) are yet to bid for the IPO so far.

Corona Remedies IPO Day 1 LIVE: A comparison of Corona Remedies with its listed peers

Corona Remedies IPO Day 1 LIVE: Corona Remedies generates 96% of revenue from India, insulating the business from US FDA risks while leading in the niche Women’s Healthcare and Pain Management segments. It records a 16.8% CAGR — nearly double the industry average (~9%) — which justifies the premium 43x P/E valuation. The company demonstrated exceptional M&A capability by scaling the acquired ‘Myoril’ brand 3x (from ₹28 crore to ₹90 crore ) in just two years, said Swastika Investmart.

Long-term sustainability is backed by a vast Medical Representative (MR) network, backward integration, and a new dedicated hormone facility. Corona Remedies IPO is fundamentally strong and fairly priced, supported by healthy margins and a favorable mix of chronic therapies, it added.

The brokerage firm has a ‘Subscribe’ rating for Corona Remedies IPO.

Corona Remedies IPO Day 1 LIVE: Corona Remedies is an India-focused branded formulations player with strong presence in women’s healthcare, cardio-diabeto, pain management and urology, and was the fastest-growing among the top 30 IPM (Indian Pharmaceutical Market) companies in MAT (Moving Annual Turnover) Jun-24 to Jun-25 with a 13.58% CAGR versus the IPM’s 7.90%. Between MAT Jun-22 and Jun-25, Corona Remedies delivered a 16.77% CAGR, over 1.82× the IPM’s 9.21% growth, supported by 5.70% volume growth and 4.57% contribution from new launches.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO has been subscribed 29% so far, according to NSE data as of 12:10 PM on Monday, the first day of the bidding period. The public issue is booked 44% in the Retail Individual Investors category, and 30% in the Non-Institutional Investors (NII) segment. The Qualified Institutional Buyers (QIB) are yet to bid for the IPO so far.

Corona Remedies IPO Day 1 LIVE: At the upper price band, Corona Remedies IPO is valued at 43x PE and 11x PB, broadly aligned with peer multiples, offering investors exposure to a business that has consistently outpaced the Indian Pharmaceutical Market (IPM). Canara Bank Securities recommends subscribing for long‑term wealth creation, suitable for investors with a medium to high-risk appetite, given the company’s superior growth momentum, competitive positioning, and scalable opportunities in the Indian pharmaceutical sector.

Corona Remedies IPO Day 1 LIVE: Corona Remedies has delivered a robust financial trajectory, with topline expanding from ₹884 crore in FY23 to ₹1,196 crore in FY25, reflecting a 16.3% CAGR. Profitability has scaled meaningfully, with EBITDA rising from ₹135 crore to ₹246 crore (35% CAGR) and PAT increasing from ₹85 crore to ₹149 crore (32% CAGR) over the same period.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO is entirely an Offer for Sale (OFS) issue. The company will not receive any money from the IPO, as all the proceeds will go to the selling shareholders. The promoters selling the shares in the OFS are Kirtikumar Mehta, Minaxi Mehta, Dipabahen Mehta, and Brinda Mehta. Other investors participating in the OFS include Sepia Investments Limited, Anchor Partners and Sage Investment Trust.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO has been subscribed 16% so far, according to NSE data as of 10:55 AM on Monday, the first day of the bidding period. The public issue was booked 24% in the Retail Individual Investors category, and 18% in the Non-Institutional Investors (NII) segment. The Qualified Institutional Buyers (QIB) are yet to bid for the IPO so far.

Corona Remedies IPO Day 1 LIVE: A look at Corona Remedies IPO key details

Corona Remedies IPO Day 1 LIVE: Corona Remedies shares are commanding a strong grey market premium (GMP) in the unlisted market. According to websites tracking the unlisted market, Corona Remedies IPO GMP today is ₹290 per share. This means that in the grey market, Corona Remedies shares are trading higher by ₹290 than their issue price.

Corona Remedies IPO GMP today signals that in the grey market, the stock is trading at ₹1,352 apiece, which is at a premium of 27.31% to the IPO price of ₹1,062 per share.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO lot size is 14 shares, and the minimum investment amount required by retail investors is ₹14,868.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO price band is set at ₹1,008 to ₹1,062 per share. At the upper-end of the price band, the company aims to raise ₹655.37 crore from the book-building issue, which is entirely an offer for sale of 61.71 lakh equity shares.

Corona Remedies IPO Day 1 LIVE: Corona Remedies IPO opens on Monday, December 8, and will close on Wednesday, December 10. The IPO allotment date is likely December 11, and the IPO listing date is December 15. Corona Remedies shares will be listed on both the stock exchanges, BSE and NSE.

Corona Remedies IPO Day 1 LIVE: The initial public offering (IPO) of pharma company Corona Remedies Ltd opens for subscription today, 8 December 2025. Corona Remedies is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.